Central nervous system effects of celastrol, a potent antioxidant and antiinflammatory agent

CNS Drug Reviews

Volumn 6, Issue 1, 2000, Pages 45-62

  Allison, Anthony C ^a   Cacabelos, R ^b   Lombardi, V R M ^b   Alvarez X A ^b   Vigo, Carmen ^c  

^a 1060 E Meadow Circle   (United States)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

^c Neurocal Inc   (United States)

Author keywords

Alzheimer's disease; Antiinflammatory; Antioxidant; Celastrol; CNS

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; CARBONYL DERIVATIVE; CELASTROL; INTERLEUKIN 1BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL ACTIVATION; CELL DAMAGE; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME INHIBITION; LEARNING; LIPID PEROXIDATION; LYMPHOCYTE PROLIFERATION; MEMORY; MICROGLIA; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PSYCHOMOTOR ACTIVITY; RAT; REVIEW;

EID: 0034107461     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2000.tb00137.x     Document Type: Review

References (60)

1. Akiyama H, Kawamata T, Dedhar S, McGeer PL. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer's brain tissue. J Neuroimmunol 1991;2:19-28.
2. Ando Y. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J Neurol Sci 1998;156:172-176.
3. Baeuerle PA, Henkel T. Function and activities of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-179.
4. Bagasra D, Michaels FH, Zheng IM, et al. Activation of inducible nitric oxide synthase in brains of patients with multiple sclerosis. Proc Natl Acad Sci USA 1995;92:12041-12045.
5. Banati RB, Gehrmann J, Czech C, et al. Early and rapid de novo synthesis of amyloid βA4-amyloid precursor protein (APP) in activated microglia. Glia 1993;9:199-210.
6. Banati RB, Rothe G, Krensberg GW, Valet G. Respiratory burst in brain macrophages. A flow cytometric study on cultured rat macrophages. Appl Neurobiol 1991;17:223-230.
7. Baszler TV, Zachary JF. Murine retroviral neurovirulence correlates with an enhanced ability of virus to infect selectively, replicate in, and activate resident microglial cells. Am J Pathol 1991;38:655-671.
8. Bereta J, Bereta M, Allison AC, et al. Inhibitory effect of di-catechol rooperol on VCAM-I and iNOS expression in cytokine-stimulated endothelium. Life Sci 1997;60:325-334.
9. Blanc EM, Kelly JF, Mark RJ, Waeg G, Matsson MP. 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors. Possible action on G-alpha (glu). J Neurochem 1995;69:570-580.
10. Cacabelos R, Álvarez XA, Fernández-Novoa L, et al. Brain interleukin-1β in Alzheimer's disease and vascular dementia. Meth Find Exp Clin Pharmacol 1994;16:141-151.
11. Cacabelos R, Barquero M, García P, et al. Cerebrospinal fluid interleukin-1β in Alzheimer's disease and neurological disorders. Meth Find Exp Clin Pharmacol 1991;13:455-458.
12. Cacabelos R, Fernández-Novoa L, Franco-Maside A, Álvarez XA. Neuroimmune functions of brain histamine: Implications for neurotrophic activity and neurotoxicity. Ann Psychiatry 1992;3:147-200.
13. Cacabelos R, Yamatodani A, Niigawa H, et al. Brain histamine in Alzheimer's disease. Meth Find Exp Clin Pharmacol 1989;11:353-360.
14. Cleeter MWJ, Cooper JM, Schapira AHV. Irreversible inhibition of mitochondrial complex 1 by 1-methyl-4-pyridinium: Evidence for free-radical involvement. J Neurochem 1992;58:786-789.
15. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous infusion of meperidine analogue. Psych Res 1979;1:249-254.
16. Dumont FJ, Eugui EM, Allison AC. Assays for small molecules with immunosuppressive activity. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, eds. Weir's Handbook of Experimental Immunology, 4th ed. Oxford: Blackwell Science 1996;4:212.1-212.16.
17. Eikelenboom P, Zhou SS, van Gool WA, Allsop D. Inflammatory mechanism in Alzheimer's disease. TIPS 1994;15:447-450.
18. Eugui EM, DeLustro B, Rouhafza S, et al. Some antioxidants inhibit in a co-ordinate fashion the production of tumor necrosis factor-α, IL-1β and IL-6 by human peripheral blood mononuclear cells. Int Immunol 1994;6:409-422.
19. Fernández-Novoa L, Cacabelos R. The histaminergic system in Alzheimer's disease. Ann Psychiatry 1995;5:127-158.
20. Ferran C, Millan MT, Czismadia V, et al. Inhibition of NF-κB by pyrrolidine dithiocarbonate blocks endothelial cell activation. Biochem Biophys Res Comm 1995;214:212-223.
21. Frackowiack J, Wisniewski HM, Wegiel J, et al. Ultrastructure of microglia that phagocytose amyloid and microglia that produce beta-amyloid fibrils. Acta Neuropathol (Berlin) 1992;84:225-233.
22. Hauke C, Korr H. RCA-I lectin histochemistry after trypsination enables the identification of microglial cells in the thin paraffin sections of the mouse brain. J Neurosci Meth 1993;50:273-277.
23. Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of β-amyloid and IFN-γ. Brain Res 1995;692:202-214.
24. Griffin WST, Stanley LC, Ling C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 1989;86:7611-7615.
25. Johnson TM, Yu Z-X, Ferrous VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 1996;93:11848-11852.
26. Kostura MJ, Allison AC. Inhibition by small molecules of the production of the pro-inflammatory cytokines TNF-α and IL-1β. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, eds. Weir's Handbook of Experimental Immunology, 4th ed. Oxford: Blackwell Science 1996;4:219.1-219.9.
27. Kruman I, Bouce-Keller AJ, Bredesen D, et al. Evidence that 4-hydroxynonenal mediates oxidation stress-induced neuronal apoptosis. J Neurosci 1997;17:5089-5100.
28. Kutney JP, Hewitt GA, Kurihara T, et al. Cytotoxic diterpenes triptolide, tripdiolide, and cytotoxic triterpenes from tissue cultures of Tripterygium wilfordii. Can J Chem 1981;59:2677-2683.
29. Lei W, Li XY. Effects of celastrol on IL-1 and IL-2 production. Pharmacol Clin Chin Mat Med 1991;7:15-17.
30. Lei W, Li XY. Immune suppressive actions of celastrol, a triterpene compound from Tripterygium wilfordii. Pharmacol Clin Chin Mat Med 1991;7:18-23.
31. Leist M. Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Eur J Neurosci 1998;9:488-498.
32. Leszek J, Dobranska I, Gasiorowski K. Alzheimer's disease. Immunopathological aspects. Acta Neurobiol Exp 1993;53:351-355.
33. Lombardi VRM, García M, Cacabelos R. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J Neurosci Res 1998;54:539-553.
34. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Ageing 1996;18:457-461.
35. Luber-Narod J, Rogers J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci Lett 1998;94:17-22.
36. Malen PL, Chapman PF. Nitric oxide facilitates long-term potentiation, but not long-term depression. J Neurosci 1997;17:2646-2652.
37. Maneiro E, Lombardi VRM, Cacabelos, R. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds. Ann Psychiatry 1996;6:331-365.
38. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Matsson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death in Alzheimer's disease. J Neurochem 1997;68:255-264.
39. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Ageing 1998;19:33-36.
40. McCarthy KD, De Vellis J. Preparation of separate astroglial and oligodendroglial cultures from rat cerebral tissue. J Cell Biol 1980;85:890-892.
41. McGeer PL, McGeer EG. The inflammatory response system of the brain: Implications for the therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1996;21:195-218.
42. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47:425-432.
43. Miller OPR. Neurological disease. Adv Pharmacol 1997;38:557-580.
44. Mogi M, Harada M, Kuichi K, et al. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in Parkinson's brain. J Neurol Trans 1988;72:77-81.
45. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, neurophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.
46. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37.
47. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease beta-amyloid protein via the scavenger receptor. Neurology 1996;17:553-565.
48. Rothwell NI, Relton JK. Involvement of cytokines in acute neurodegeneration in the CNS. Biobehav Res 1993;17:217-227.
49. Sassa H, Takaishi Y, Terada H. The triterpene celastrol is a very potent inhibitor of lipid peroxidation in mitochondria. Biochem Biophys Res Comm 1990;172:890-897.
50. Sassa H, Kogure K, Terada H. Structural basis of potent antiperoxidative activity of the triterpene celastrol in mitochondria: Effect of negative membrane surface charge on lipid peroxidation. Free Radical Biol 1994;17:201-207.
51. Shigematsu K, McGeer PL, Walker DG, et al. Reactive microglia/macrophages phagocytose amyloid precursor proteins produced by neurons following neural damage. J Neurosci Res 1992;31:443-453.
52. Smith MA, Harris PL, Sayre LM, et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-2657.
53. Southam E, Thomas PK, King RMH, Goss-Sampson MA, Miller DPR. Experimental vitamin E deficiency in rats: Morphological and functional evidence of abnormal axonal transport secondary to free radical damage. Brain 1991;114:915-936.
54. Styren SD, Cirin WH, Rogers J. Molecular, cellular and pathological characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol 1990;110:93-104.
55. Su JH, Deng G, Cotman CW. Neuronal damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain. Brain Res 1997;774:193-199.
56. Svennerholm L, Gottfries CG. Membrane lipids, selectively decreased in Alzheimer's brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 1994;62:1039-1047.
57. Tao XL, Sun Y. Prospective, controlled, double-blind crossover trial of T2 (polyglycosides extracted from Tripterygium wilfordii Hook F) in the treatment of rheumatoid arthritis. Chin J Med 1987;26:399-402.
58. Uchihara T, Akiyama H, Kondo H, Ideda K. Activated microglial cells are colocalized with perivascular deposits of amyloid-β protein in Alzheimer's disease brain. Stroke 1997;28:1948-1950.
59. Willerson JT. Pharmacological approaches to reperfusion injury. Adv Pharmacol 1998;39:291-312.
60. Yan S-D, Chen X, Schmidt A-M, et al. Glycated tau protein in Alzheimer's disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-77891.